Format

Send to:

Choose Destination
See comment in PubMed Commons below
Acta Neurol Scand. 2001 Apr;103(4):226-30.

Losigamone add-on therapy in partial epilepsy: a placebo-controlled study.

Author information

  • 1Department of Epileptology, University of Bonn, Germany, Dr Willmar Schwabe GmbH, Karlsruhe, Germany.

Abstract

OBJECTIVES:

To evaluate the efficacy and tolerability of losigamone (LSG).

PATIENTS AND METHODS:

Double-blind, placebo-controlled add-on study with 3x500 mg LSG/die for the treatment of chronic partial seizures in 203 patients (99 treated with LSG, 104 on placebo).

RESULTS:

The median percent change of seizures was 14.9% (LSG) versus 6.7% (placebo) (P=0.004). Seizure frequency was decreased by more than 50% in 22.3% (LSG) and 14.6% (placebo) of patients (P=0.13). Mean percent change of seizures was best in patients with only one additional anticonvulsant drug (LSG versus placebo, P=0.004). Adverse events (usually CNS-related side effects of mild to moderate intensity) were reported in 59.6% (LSG) and 37.5% (placebo) of patients.

CONCLUSIONS:

LSG proved to be an effective and well tolerated anticonvulsant drug for the treatment of chronic partial seizures.

PMID:
11328193
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk